Meeting
2021 ASCO Annual Meeting
CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.
Authors
Catherine Thieblemont
AP-HP at Saint-Louis Hospital, Hemato-oncology, Paris University, Paris, France
Catherine Thieblemont , Bettina Altmann , Olivier Casasnovas , Fabian Frontzek , Franck Morschhauser , Lucie Oberic , Viola Poeschel , Olivier Fitoussi , Loïc Renaud , Georg Lenz , Nicolas Mounier , Andreas Rosenwald , German Ott , Thierry Molina , Marie Parrens , Loic Chartier , Marita Ziepert , Herve Tilly , Norbert Schmitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7543)
DOI
10.1200/JCO.2021.39.15_suppl.7543
Abstract #
7543
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Patterns of use of CNS prophylaxis in DLBCL in a large health system.
First Author: Michael A. Thompson
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2021 ASCO Annual Meeting
Long-term follow-up results of a phase II study of dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).
First Author: Kana Miyazaki